Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Common Equity (2021 - 2025)

Historic Common Equity for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to -$20.3 million.

  • Pharmaceuticals' Common Equity fell 10022.51% to -$20.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$20.3 million, marking a year-over-year decrease of 10022.51%. This contributed to the annual value of $1.9 million for FY2024, which is 9999.23% down from last year.
  • As of Q2 2025, Pharmaceuticals' Common Equity stood at -$20.3 million, which was down 10022.51% from -$8.1 billion recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Common Equity ranged from a high of $24.2 billion in Q4 2023 and a low of -$8.1 billion during Q1 2025
  • For the 5-year period, Pharmaceuticals' Common Equity averaged around $3.2 billion, with its median value being $30.0 million (2022).
  • In the last 5 years, Pharmaceuticals' Common Equity surged by 5411321.85% in 2023 and then plummeted by 5227559.97% in 2025.
  • Over the past 5 years, Pharmaceuticals' Common Equity (Quarter) stood at $84.5 million in 2021, then plummeted by 47.25% to $44.6 million in 2022, then skyrocketed by 54113.22% to $24.2 billion in 2023, then crashed by 99.99% to $1.9 million in 2024, then tumbled by 1197.24% to -$20.3 million in 2025.
  • Its Common Equity was -$20.3 million in Q2 2025, compared to -$8.1 billion in Q1 2025 and $1.9 million in Q4 2024.